Investigation of susceptibility of influenza viruses A (HlNl), the cause of infection in humans in april - may 2009, to antivirals in MDCK cell culture

Antibiotiki i Khimioterapiya

Volumn 54, Issue 5-6, 2009, Pages 41-47

  Romanovskaya, A A ^a   Durymanov, A M ^a   Sharsov, K A ^a   Zaikovskaya, A V ^a   Susloparov, I M ^a   Shestopalov, A M ^a   Leneva, I A ^a   Drozdov, I G ^a  

^a NONE

Author keywords

Arbidol; Cell culture; Influenza virus a (h1n1); Ribavirin; Rimantadine; Virus inhibition activity

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; INDOLE DERIVATIVE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RIBAVIRIN;

AMINO ACID SUBSTITUTION; ANIMAL; ANTIVIRAL RESISTANCE; ARTICLE; CELL LINE; DOG; DRUG EFFECT; GENETICS; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; MISSENSE MUTATION; PHYSIOLOGY; VIRUS GENOME; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HUMANS; INDOLES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION, MISSENSE; RIBAVIRIN; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

INFLUENZAVIRUS A; ORTHOMYXOVIRIDAE;

EID: 70449090408     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Emergence of novel swine-origin influenza A (HlNl) virus in human. Novel swine-origin influenza A (HlNl) virus investigation team. The New England Journal of Medicine 2009; 10:1-10.
2. FDA. Antiviral Drug Advisory Committee. Gaithersburg: Centre for Drug Evaluation and Research 2002; 1-266.
3. Zlydnikov D. M., Kubar O. I., Kovaleva T. P. et al. Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis 1981; 3: 408-421.
4. Hayden F. WHO guidelines on the use of vaccines and antivirals during influenza. Annex 5-considerations for the use of antivirals during an influenza pandemic, Geneva, 2-4 October, 2002.
5. Glushkov R. G. Arbidol. Antiviral, immunostimulant, interferon inducer. Drug Future 1992; 17: 1079-1081.
6. 7. Rodriguez W. J., Hall C. B., Welliver R. et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 1994; 125: 129-135 (Pubitemid 24225195)
7. MMWR Morb Mortal Wkly Rep. Update: drug susceptibility of swineorigin influenza A (HlNl) viruses, April 2009.Centers for Disease Control and Prevention (CDC) 2009; 58: 433-435.
8. 9. Meguro, H., Bryant, J. D., Torrence, A. E., Wright, P. F. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 1979; 9: 175-179. (Pubitemid 9123778)
9. Gambaryan A. S., Tuzikov A. B., Piskarev V. E. et al. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolimers non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'sialyl(N-acetyllactosamine). Virology 1997; 232: 345-350.
10. 13. Ward A. Virulence of influenza A virus for mouse lung. Virus Genes 1997; 14: 187-194. (Pubitemid 27397054)
11. Hay A. Amantadine and Rimantadine Mechanisms. In book: Antiviral Drug Resistance, D.Richman (ed), John Willey and Sons Ltd, UK. 1996; 44-58.
12. 15. Monto A. Viral susceptibility and the choice of influenza antivirals. Clinical Infectious Diseases 2008; 47: 346-348. (Pubitemid 352009353)
13. Leneva I. A., Russell R. J., Boriskin Y. S., Hay A. J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 2009.
14. Avian influenza A (H5N1) infection in humans. The writing Committee of the WHO Consultation on human influenza A/H5. New Engl J Med 2005; 353: 1374-1385.
15. Crotty S., Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Med Chem. 2002; 80: 86-95.